Biosimilars 101: considerations for U.S. oncologists in clinical practice

por Camacho, Luis H, Frost, Craig P, Abella, Esteban, Morrow, Phuong K, Whittaker, Sadie
Publicado 2014

Appropriateness of granulocyte colony-stimulating factor use in patients receiving chemotherapy by febrile neutropenia risk level

por Baig, Hassam, Somlo, Barbara, Eisen, Melissa, Stryker, Scott, Bensink, Mark, Morrow, Phuong K
Publicado 2018

Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics

por Carter, Bing Z., Mak, Po Yee, Tao, Wenjing, Ayoub, Edward, Ostermann, Lauren B., Huang, Xuelin, Loghavi, Sanam, Boettcher, Steffen, Nishida, Yuki, Ruvolo, Vivian, Hughes, Paul E., Morrow, Phuong K., Haferlach, Torsten, Kornblau, Steven, Muftuoglu, Muharrem, Andreeff, Michael
Publicado 2023

Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics

por Carter, Bing Z., Mak, Po Yee, Tao, Wenjing, Ayoub, Edward, Ostermann, Lauren B., Huang, Xuelin, Loghavi, Sanam, Boettcher, Steffen, Nishida, Yuki, Ruvolo, Vivian, Hughes, Paul E., Morrow, Phuong K., Haferlach, Torsten, Kornblau, Steven, Muftuoglu, Muharrem, Andreeff, Michael
Publicado 2023